Unveiling changes in the landscape of patient populations in cancer early drug development

The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Hierro, Cinta, Azaro, Analía, Argilés, Guillem, Elez, Elena, Gómez, Patricia, Carles, Joan, Rodon, Jordi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355170/
https://ncbi.nlm.nih.gov/pubmed/27835915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13258
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk